Global Oligonucleotide Therapeutics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Oligonucleotide Therapeutics Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

“Oligonucleotide therapeutics” is a general term for state-of-the-art, molecular-target agents that employ chemically synthesized oligonucleotides with a single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) backbone with potential specificity. These agents can inhibit gene expression or impede protein function by binding to a specific sequence of a target gene or protein.

Market Overview:

The latest research study on the global Oligonucleotide Therapeutics market finds that the global Oligonucleotide Therapeutics market reached a value of USD 4252.28 million in 2022. It’s expected that the market will achieve USD 10893.76 million by 2028, exhibiting a CAGR of 16.97% during the forecast period.

Oligonucleotide therapeutics are a new type of drug, which consists of short synthetic nucleotides with high specificity and target molecules (such as mRNA or non-coding RNA) that cannot be controlled by conventional drugs. Oligonucleotide therapeutics are chemically synthesized drug whose main skeleton is chemically modified nucleotides. These nucleotide technologies make it possible to produce cutting-edge gene drugs, including tissue-specific nucleic acid bio-conjugates, mRNA, gene therapy, and gene-editing treatments. Importantly, nucleic acid delivery technology is currently the core of the global fight against COVID-19 pandemic.

Antisense oligonucleotide (ASO) is a single-stranded synthetic nucleic acid chains, which targets specific RNA transcripts through various mechanisms. ASO can reduce the number of mutant proteins by decomposing the target transcript, inhibiting mRNA translation or altering the maturation of the pre-mRNA via splicing correction. As time goes by, the chemical modification of ASO compounds leads to significant improvement of their pharmacological properties, making these drugs a great potential choice for the treatment of many neurodegenerative diseases.

The barriers to entry into the Drug industry are relatively high

In addition to meeting the general laws and regulations, enterprises in this industry should have the prescribed operating conditions, including legally qualified pharmaceutical technicians, engineering technicians and corresponding technical workers; It shall have factory buildings, facilities and a hygienic environment suitable for the production of pharmaceuticals; It has an organization, personnel and necessary instruments and equipment capable of conducting quality control and quality inspection of the drugs produced; There are rules and regulations to ensure the quality of drugs. Pharmaceutical industry is a high investment industry, its new product development investment is high, the cycle is long, the risk is big. Therefore, new entrants usually need a long time to start up and face great financial pressure. Pharmaceutical industry pharmaceutical technology is difficult, high equipment requirements, complex process route, production environment requirements are very strict.

Achieving effective delivery of oligonucleotide therapeutics to many tissues remains a major translational challenge.

Due to physical and chemical properties, unmodified free oligonucleotides are not only cleared by body soon after drug delivery, but also have the risk of off-target and toxic side effects. Therefore, nucleic acid drugs need chemical modification and appropriate delivery system to achieve therapeutic effect. Chemical modification plays an important role in the delivery of oligonucleotide drugs, but it is still difficult for small interfering RNA(siRNA) drugs to reach the target site only by chemical modification. The delivery of antisense oligonucleotide (ASO) drugs is also poor, which makes the delivery system crucial for the success of oligonucleotide drug development.

Region Overview:


Geographically, Americas held the largest market share – 46.76% in 2021.


Company Overview:

Biogen is one of the major players operating in the Oligonucleotide Therapeutics market, holding a share of 40.85% in 2022.

Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.
Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilar of advanced biologics.

Alnylam Pharmaceuticals

Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options.

Segmentation Overview:

By type, Antisense Oligonucleotide segment accounted for the largest share of market in 2021.

Antisense Oligonucleotide

Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein expression through several distinct mechanisms.

Small Interfering RNA

Small interfering RNA (siRNA) relies on sequence complementarity between RNAs and the target mRNAs to inhibit their activity. In particular, chemically synthesized siRNAs are mainly being used as a new class of therapeutic agents. The siRNA-based therapeutic strategy enables selective silencing of targeting gene expression. Compared with conventional anti-cancer drugs, siRNA has marked advantages, such as greater safety, stronger potency, higher specificity, and unrestricted choice of drug targets.

Application Overview:

The market's largest segment by application is the segment Neuromuscular Diseases , with a market share of 53.1% in 2021.

Neuromuscular Diseases

Neuromuscular diseases comprise a diverse group of mainly inherited conditions that typically affect muscles (including the heart muscle) and the brain, resulting in progressive degeneration of these tissues and leading ultimately to very significant morbidity and mortality.

ATTR

Amyloidogenic transthyretin (ATTR) amyloidosis is caused by aprotein called transthyretin, or TTR, that changes its shape and forms into fibrous clumps. These clumps of misshapen protein are deposited into various organs and peripheral nerves, which can cause them to function abnormally.

Hepatic VOD

Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is a rare complication characterized by hepatomegaly, right-upper quadrant pain, jaundice, and ascites, occurring after high-dose chemotherapy, hematopoietic stem cell transplantation (HSCT) and, less commonly, other conditions.

Key Companies in the global Oligonucleotide Therapeutics market covered in Chapter 3:

Biogen
Ionis Pharmaceuticals, Inc.
Jazz Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku Co.
Alnylam Pharmaceuticals

In Chapter 4 and Chapter 14.2, on the basis of types, the Oligonucleotide Therapeutics market from 2018 to 2029 is primarily split into:

Antisense Oligonucleotide
Small Interfering RNA
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Oligonucleotide Therapeutics market from 2018 to 2029 covers:

Neuromuscular Diseases
ATTR
Hepatic VOD
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)